Spots Global Cancer Trial Database for intensive chemotherapy
Every month we try and update this database with for intensive chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma | NCT00965289 | B-Cell Lymphoma | Rituximab | 18 Years - 60 Years | Nantes University Hospital | |
| Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | NCT01074047 | Acute Myeloid L... | Azacitidine Conventional Ca... | 65 Years - | Celgene | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | NCT05356169 | Acute Myeloid L... | with or without... | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma | NCT00965289 | B-Cell Lymphoma | Rituximab | 18 Years - 60 Years | Nantes University Hospital | |
| Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. | NCT06409767 | Leukemia Lymphoma Multiple Myelom... | Real-time calcu... | 18 Years - | University Hospital, Angers | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition | NCT03284593 | Acute Myeloid L... | intensive chemo... Azacitidine | 18 Years - | University Hospital, Toulouse | |
| Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. | NCT06409767 | Leukemia Lymphoma Multiple Myelom... | Real-time calcu... | 18 Years - | University Hospital, Angers | |
| Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML | NCT01496547 | Acute Leukemia | intensive chemo... | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
